MEK/BRAF Inhibition May Overcome Molecular Heterogeneity of BRAF-Mutant Melanoma

Leggi l'articolo originale


Deeper inhibition of the MAPK pathway by targeting both MEK and BRAF may help improve progression-free survival outcomes in patients with advanced BRAF V600–mutated melanoma.

Lascia un commento